CA Patent

CA2666398A1 — Diclofenac gel

Assigned to Aralez Pharmaceuticals Canada Inc · Expires 2008-04-24 · 18y expired

What this patent protects

The present invention provides a gel formulation comprising diclofenac so dium which has superior transdermal flux properties, which may be used for t he topical treatment of pain, such as in osteoarthritis.

USPTO Abstract

The present invention provides a gel formulation comprising diclofenac so dium which has superior transdermal flux properties, which may be used for t he topical treatment of pain, such as in osteoarthritis.

Drugs covered by this patent

Patent Metadata

Patent number
CA2666398A1
Jurisdiction
CA
Classification
—
Expires
2008-04-24
Drug substance claim
No
Drug product claim
No
Assignee
Aralez Pharmaceuticals Canada Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.